Idiopathic pulmonary fibrosis: state of the art for 2023
The DOI matches its Crossref record; 188 of the 196 references it cites were found in a registry or an index.
Abstract
Review noting that IPF is a progressive fibrotic lung disease characterized by worsening respiratory symptoms and physiological impairment, while the individual patient course and rate of disease progression are often unpredictable and heterogeneous.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Up to now, the specific therapeutic drugs that reverse IPF or halt the progression of IPF are still unavailable due to the incomplete understanding of the pathogenesis of IPF 5.”
From Nicotinamide phosphoribosyltransferase prompts bleomycin-induced pulmonary fibrosis by driving macrophage M2 polarization in mice (2024) · cites this paper as [5]
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citation(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citation
Research works printed but not linked: 1
- 10.1186/s12931-019 · doi:10.1186/s12931-019
Cited by
Items 201–300 of 354
Wilson, J.-A. A. M., Walters, R., Guillotin, D., Kaminski, N., Parolo, S., Platé, M., & Chambers, R. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.12.617979 · Cited by 2
“In spite of the introduction of the first approved anti-fibrotic agents, pirfenidone and nintedanib, life expectancy remains at 3-5 years from diagnosis as these agents slow but do not halt disease progression (2 – 4).”
BackgroundQuimbita, J. E. T., & Velasteguí, V. G. S. (2024) · Mediciencias UTA (Impresa)/Mediciencias UTA (En línea) · doi:10.31243/mdc.uta.v8i1.2307.2024 · Cited by 1
Repositioning compounds for idiopathic pulmonary fibrosis treatment: seeking the future in the past
Crestani, B. (2024) · European Respiratory Journal · doi:10.1183/13993003.00678-2024 · Cited by 1
Prevalence, Clinical Features, and Outcomes of Young Patients with Idiopathic Pulmonary Fibrosis
Lee, J., Kim, K., Nam, J. H., Choi, J. Y., Rhee, C. K., & Jo, Y. S. (2024) · Respiration · doi:10.1159/000541692 · Cited by 3
“Smoking cessation education, targeting a known risk factor, supplementary oxygen use if hypoxemic, managing comorbidities, along with the administration of anti fi brotic agents to inhibit the progression of the disease have recently become crucial components of the treatment paradigm [9, 24].”
Perrotta, F., Lacedonia, D., D’Agnano, V., Bianco, A., Scioscia, G., Tondo, P., Barbaro, M. P. F., Mariani, F., Lettieri, S., Frate, L. D., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1488157 · Cited by 1
Shen, C., Wang, W. T., Wei, D., Yang, X., Jiang, C., Sheng, Y., Chen, Y., Sun, J., Li, X. A., Li, G., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03555-7 · Cited by 1
“Due to the irreversible nature of IPF and its poor prognosis and the fact that the two currently approved antifibrotic agents for treating IPF (pirfenidone and nin-tedanib) only impede disease progression but do not cure it, the search for effective drug targets is vital [52, 53].”
Clinical relevance of microvascular endothelial dysfunction in idiopathic pulmonary fibrosis
Pastré, J., Salvator, H., Henno, P., Günther, S., Chabrol, A., Grassin‐Delyle, S., Israël‐Biet, D., & Devillier, P. (2025) · ERJ Open Research · doi:10.1183/23120541.01265-2024 · Cited by 1
“Four AE-IPF occurred during the 3-year follow-up period; this was in line with the typical rate of 5 – 10% of patients per year [1].”
Common and rare variants and survival in idiopathic pulmonary fibrosis
Manali, E. D., Kannengiesser, C., & Papiris, S. A. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00116-x · Cited by 1
Yohannes, A. M. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2523501 · Cited by 1
“Early signs and symptoms in ILD patients may include exertional dyspnea, cough, fatigue, restrictive patterns on pulmonary function tests (PFTs), and bilateral fibrotic patterns on chest imaging [6,7].”
Deniz, P. P., Köse, S., Hanta, İ., Çetinkaya, P. D., Arslan, M. S., & Datlı, E. (2025) · Medicina · doi:10.3390/medicina61071181 · Cited by 1
“Patient-related factors associated with a higher risk of acute exacerbation include low FVC, reduced DLCO, decreased six-minute walk distance, pulmonary hypertension, poor baseline oxygenation, increased dyspnea, and a decline in FVC during follow-up [25].”
Ren, Q., Pan, Y., Tian, Z., Jiao, G., & Liu, X.-M. (2025) · Cell Biology International · doi:10.1002/cbin.70051 · Cited by 1
“…marked by alveolar epithelial damage, increased ECM deposition, enhanced fibroblast ‐ to ‐ myofibroblast transition, and accelerated myofibroblast proliferation (Koudstaal et al. 2023; Moss et al. 2022; Podolanczuk et al. 2023; Richeldi et al. 2017; Spagnolo et al. 2021; Thannickal et al. 2004).”
Pang, X., Cheng, L., Huang, L., He, W., Liu, S., Wang, Y., Zheng, J., Peng, L., & Yang, T. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2025-194 · Cited by 4
“IPF commonly occurs in the elderly population and is characterized by symptoms including progressive dyspnea, declining lung function, and ultimately respiratory failure (3,4).”
Recent advances in drug delivery systems for pulmonary fibrosis therapy
Yu, Y., Gan, C., Shi, K., Bei, Z., Yang, Y. P., Pan, M., Deng, H., & Qian, Z. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111596 · Cited by 5
Tagami, Y., Kawai, M., Okamura, K., & Kitamura, H. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0021 · Cited by 1
Borghetti, P., D’Angelillo, R. M., Facheris, G., Borghesi, A., Bruni, A., Ceruti, P., Ferrari, K., Filippi, A. R., Ramella, S., Signorelli, D., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108807 · Cited by 2
Indentation mechanics of healthy and fibrotic murine lung reveals homogeneous surface stiffness
Quiros, K. A. M., Nelson, T. M., & Eskandari, M. (2025) · Results in Engineering · doi:10.1016/j.rineng.2025.108312 · Cited by 2
Hu, M., Wan, Y., Chen, J., Zhang, C., Li, S., Shan, B., Wu, L., & Yu, X. M. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102659 · Cited by 2
“PF is characterized by the formation of many fibroblast foci, which leads to considerable extracellular matrix accumulation and remodeling of the lung inter-stitium [1,2].”
Hussein, M., Suliman, A. M., Kalfah, A., Magboul, H., Alsayed, A. A., Alwassiti, W., Salman, A., Alateeg, S., Saied, A. S., Alkhateeb, E., et al. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.102687 · Cited by 1
Yang, L., Liu, L., Liao, Y., Zou, J., Jiang, C., Liu, X., & Jun-mei, S. (2025) · Human Genomics · doi:10.1186/s40246-025-00845-3 · Cited by 3
“IPF progression is typically unpredictable, manifesting either as a steady decline in lung function or as abrupt exacerbations [1].”
Cao, Y., Liao, X., Huang, P., Lu, R., Wu, Q., Zhong, K., Wang, X., Yang, Y., Liu, X., Fan, J.-J., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118505 · Cited by 2
Singh, P., Patel, P. K., Kasam, R. K., Lawson, R., Ediga, H. H., Jegga, A. G., & Madala, S. K. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00204.2025 · Cited by 1
“IPF is diagnosed primarily in individuals over the age of 60; it has an estimated global incidence of 1–13 cases per 100,000 persons, with the highest rates reported in South Korea, Canada, and North America (3, 4).”
Zhang, W., Xia, T., & Zhang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1697013 · Cited by 1
Raith, J., Ruwisch, J., Schupp, J. C., Graalmann, T., Drick, N., Hoeper, M. M., Prasse, A., Fuge, J., Ringshausen, F. C., Knegendorf, L., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03497-6 · Cited by 1
“Even though some cohorts and large registries report similar use of systemic corticosteroid [51–54], immunosuppression in IPF should be avoided outside of acute exacerbation [55].”
Targeting sorting nexin 3 to treat pulmonary fibrosis by dual modulating Wnt/β-catenin signaling
Ma, D., Yu, W., Zhou, H., Lin, R., Sun, X., Peng, M., Lin, C., Du, H., Li, Y., Liang, H., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08248-x · Cited by 1
“Currently, treatment options for PF remain limited, and most research focuses on the development of anti-fi brotic drugs [22 – 24].”
CXCR2 antagonism as a promising therapeutic approach for pulmonary fibrosis therapy
Melo, E. M., Resende, F., Ascenção, F. R., Queiroz‐Junior, C. M., Amatruda, M., Tomassetti, M., Brandolini, L., Bianchini, G., Aramini, A., Soriani, F. M., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.118998 · Cited by 1
New insights into idiopathic pulmonary fibrosis epidemiology in the United States
Jeganathan, N. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoaf058 · Cited by 2
Cao, X., Kuang, S., Jiang, K., He, Y., Luo, F., Li, Y., Zhang, M., He, D., & Liang, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1717994 · Cited by 2
“With population aging, increased air pollution, and other high-risk exposures, the global burden of IPF has been projected to continue rising (Podolanczuk et al., 2023).”
Zhang, J., Gao, W., Chao, B., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1798039 · Cited by 1
“Previous studies have identified age as an independent risk factor for IPF, where UIP serves as the core radiographic manifestation (34, 35).”
A Lung-Targeted Carrier of Carbon Monoxide for Idiopathic Pulmonary Fibrosis Therapy
Guo, W., Huang, S., Zhang, J., Zhang, X., Yang, J., Bao, Y., & Zhang, J. (2026) · ACS Nano · doi:10.1021/acsnano.6c01762 · Cited by 1
Li, J. S., Li, H., Wang, X., Wang, C., Sun, J., Qu, C., & Tian, H. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c01140 · Cited by 1
Bao, Y., Zhao, H., Yang, S., Zhang, T., Liu, M., & Zhu, X. L. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08142-w · Cited by 1
“The rate of disease progression in individual patients is difficult to predict, resulting in significant unpredictability and heterogeneity [1].”
Morimoto, T., Ishikane, S., Arioka, M., Hashimoto, K., Igawa, K., Higashi, Y., Tomonaga, T., Nishida, C., Yatera, K., & Takahashi‐Yanaga, F. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101429 · Cited by 1
Vascular targeted therapies for fibrotic lung disease: start of a new era?
Tyker, A., Price, L. C., Nathan, S. D., & Kolb, M. R. J. (2026) · European Respiratory Journal · doi:10.1183/13993003.00285-2026 · Cited by 2
Self-citationC/EBPγ interacts with C/EBPα and activates the β-catenin pathway in idiopathic pulmonary fibrosis
Pan, X., Xia, C., Gan, Y., Cao, Y., Zhao, M., Liu, H., Zhou, Y., Wang, Y., Li, Z., Li, B., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06245-7 · Cited by 1
Advances in diagnosis of lung fibrosis: focus on present and future approaches
Fadelelmoula, T. E. Y., Mutori, H. A., Mohammed, K., Al-rudaini, M., & Reesi, A. A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1847987 · Cited by 2
Tan, Q., ZHAO, Y., Zhang, Y., Chen, H., Xu, Z., Pan, Z., El‐Khouly, M. E., & Yuan, Y. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09336 · Cited by 7
ERJ2024: your journal, my journal, our journal
Sin, D. D., & Chalmers, J. D. (2024) · European Respiratory Journal · doi:10.1183/13993003.02215-2023 · Cited by 1
Adenophorae Radix Reduces Fibrosis in a Bleomycin-Induced Pulmonary Fibrosis Mouse Model
Kim, E.-J., Park, J.-W., Yu, C.-H., Park, J.-W., Kim, K., Jung, H.-J., Kim, J.-H., Bu, Y., & Lee, B. (2024) · Natural Product Communications · doi:10.1177/1934578x241227490 · Cited by 1
McCubbrey, A. L., & Janssen, W. J. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202406-1164ed · Cited by 1
“However, these models struggle to replicate the clinical heterogeneity of IPF, including variability in rates of disease progression (2).”
BackgroundTranscriptional orchestration of EMT: Unraveling novel molecular targets in pulmonary fibrosis
Bobis‐Wozowicz, S., & Paw, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.012 · Cited by 1
Targeted Drug Repurposing for Idiopathic Pulmonary Fibrosis
Shivandappa, Manokaran, S., Dhanasekaran, M., Mandem, J. R., Rao, M. R., & Manasi, N. S. (2024) · International Conference on Computation System and Information Technology for Sustainable Solutions (CSITSS) · doi:10.1109/csitss64042.2024.10816991 · Cited by 1
“Idiopathic pulmonary fibrosis (IPF) is a progressive lung illness marked by the thickening and rigidity of lung tissue caused by scar tissue formation, which can proceed to fibrosis and, finally, respiratory failure [1].”
Wu, F., Li, B., Li, J., Yuan, W., Zhu, X., & Liu, X. (2025) · Biomedical Reports · doi:10.3892/br.2025.1930 · Cited by 1
Spagnolo, P., Kaner, R. J., & Raghu, G. (2025) · European Respiratory Journal · doi:10.1183/13993003.00151-2025 · Cited by 1
Self-citationSpatial Transcriptomic Characterization of Novel Pathologic Niches in IPFPreprint
Mayr, C. H., Santacruz, D., Jarosch, S., Lempp, C., Neubert, L., Rath, B., Kamp, J. C., Jonigk, D. D., Kühnel, M., Schlueter, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.13.571464 · Cited by 1
Editorial: Cellular and molecular mechanisms of lung regeneration, repair, and fibrosis
Mo, C., Yan, M., Tang, X. X., Shichino, S., & Bagnato, G. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1346875 · Cited by 2
How does the MESA Lung Study sharpen blurry edges in interstitial lung abnormalities?
Brillet, P., Ba, S. T., & Nunès, H. (2023) · European Respiratory Journal · doi:10.1183/13993003.00397-2023
Albendazole ameliorates aerobic glycolysis in myofibroblasts to reverse pulmonary fibrosisPreprint
Zeng, C., Yue, H., Wang, C., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3690679/v1
Shin, W., Park, M. Y., Kim, J., Kim, J.-H., Nam, J. H., Choi, J., Yang, A., Yoo, H., Lee, Y., & Kim, A. (2023) · Clinical and Translational Science · doi:10.1111/cts.13701
Gómez, M. I. (2023) · International Journal of Pulmonary & Respiratory Sciences · doi:10.19080/ijoprs.2023.06.555699
Lian, H., Wan, R., Yang, K. J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4015043/v1
Tonelli, R., Smit, M. R., Castaniere, I., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3970169/v1
He, J., Liao, Z., Chen, H., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4233607/v1
Malakauskas, K., Biekšienė, K., Zaveckienė, J., Poškienė, L., Dobrovolskienė, L., Šarauskas, V., Žemaitis, M., & Miliauskas, S. (2024) · Pulmonology and allergology · doi:10.37499/pia.1419
Vos, N. D., Bruyneel, M., Roman, A., Antoine, M., Bruyneel, A.-V., Alard, S., André, S., Dahma, H., Chirumberro, A., & COTTON, F. J. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119926
Editorial of utility of the Global Lung Function Initiative (GLI) for ILD
Kishaba, T. (2024) · Thorax · doi:10.1136/thorax-2024-222356
Ding, L. (2024) · New discovery. · doi:10.61958/ndcg7201
Wang, Y., Xu, B., Wang, J., Li, S., & Xie, Y. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s498350 · Cited by 1
Liu, B., Kang, D., Zhang, J., Wang, Y., Li, R., Lv, C., Zhai, N., Song, X., Zhang, S., & Li, H. (2026) · Communications Biology · doi:10.1038/s42003-026-10125-y · Cited by 1
“Idiopathic pulmonary fi brosis (IPF) is a fatal interstitial lung disease char-acterizedbyirreversible fi broticdestructionoflungstructure 1 .”
TheEuropean Respiratory Journal: our drive to thrive in ’25!
Chalmers, J. D., Bullen, N. J., & Sin, D. D. (2025) · European Respiratory Journal · doi:10.1183/13993003.00047-2025
Borghetti, P., Angelillo, R. M. D. A., Facheris, G., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5239531
Aqil, M., Rahman, S. U., Aslam, M. Z., Ahmed, M. A. A., Ahmed, A., Javaid, S., & Haq, E. U. (2025) · Pakistan Journal of Medicine and Dentistry · doi:10.36283/ziun-pjmd14-2/059
Pagano, A., Bruni, M., Tavanti, L. M., et al. (2025) · Therapeutics · doi:10.3390/therapeutics2020009
“Although a cause-and-effect relationship has not been established, several conditions are known to promote its development, including cigarette smoke, exposure to toxic substances and environmental pollutants, gastro-esophageal reflux, and a family history of IPF [3].”
Cai, X.-X., & Yang, Y. (2025) · New cell · doi:10.61958/ncas2202
Conti, M., Casara, A., Turato, G., Baraldo, S., Tinè, M., Semenzato, U., Cocconcelli, E., Biondini, D., Damin, M., Saetta, M. P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1541645
Interstitial lung diseases: a view on the problem
Sych, O. G., Dziublyk, Y., & Liubarets, T. F. (2025) · Ukrainian Journal of Military Medicine · doi:10.46847/ujmm.2025.2(6)-024
ADVANCES IN THE DIAGNOSIS AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS - A LITERATURE REVIEW
Redel, P., & Dzwonkowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3503
Liu, B., Kang, D., Zhang, J., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5378132
Behr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00570-2025 · Cited by 2
“Idiopathic pulmonary fibrosis (IPF) is a rare, progressive and devastating lung disease characterised by irreversible scarring of lung tissue, leading to impaired lung function, reduced exercise capacity, impaired quality of life and premature death [1, 2].”
Self-citationEditorial: Cellular and molecular mechanisms of lung regeneration, repair, and fibrosis, volume II
Qiu, Y., Tang, X. X., Shichino, S., Kushwaha, P. P., Sanders, Y. Y., Russo, R. C., & Mo, C. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1653034 · Cited by 2
Zhang, X., Wu, X., Luo, C., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1604895
Oh, J. H., Park, M. S., Chung, M. P., Jeong, S. H., Song, J. W., Choi, S. M., Kim, Y. H., Park, S., Jegal, Y., Yoon, H., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1679011 · Cited by 1
“The clinical course of IPF is heterogeneous, ranging from slowly progressive disease to rapid deterioration, and patient median survival has been reported to be approximately 3–5 years post-diagnosis (1, 2).”
Justet, A., & Schupp, J. C. (2025) · European Respiratory Journal · doi:10.1183/13993003.01466-2025
Bao, H., Wu, M., Zhang, Y., Yu, Z., Li, J., & Wu, A. (2025) · ACS Materials Letters · doi:10.1021/acsmaterialslett.5c01167 · Cited by 1
Shen, C., Wang, W. T., Li, G., Wei, D., Yang, X., Jiang, C., Sheng, Y., Chen, Y., Xu, J., Ye, S., et al. (2025) · Canadian Respiratory Journal · doi:10.1155/carj/2272156
“Te disease is typically progressive, ultimately resulting in respiratory failure and death [1, 2].”
GZMK Drives Aging-Associated Fibrosis through Complement C3a/C3aR-Dependent Cellular SenescencePreprint
Duan, Y., Yang, X., Kuang, X., Chen, X., Yu, H., He, X., Guo, X., Yang, P., Yang, Y., Tong, X., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7888848/v1
Ding, J., Chen, Z., Yu, J., Xu, Y., Zhu, T., Wang, B., Feng, Z., Li, X., Qian, X., Jin, B., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117646
Multidisciplinary approach in the diagnosis and treatment of interstitial lung diseases
Бакенова, Р. А., Yessengeldinova, M., Bakieva, K. M., et al. (2025) · Journal of Respiratory Medicine · doi:10.17116/respmed2025104119
Önyılmaz, T., Barış, S. A., Ozturk, B., Kizilbay, G. Ö., Güldiken, G. S., Boyacı, H., & Başyiğit, İ. (2025) · Diagnostics · doi:10.3390/diagnostics16010074
Namboothiri, D. R., Sivanandan, A., NETTO, G., & Mathew, M. (2025) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2025.102405
Geranylgeranylacetone Alleviates Pulmonary Fibrosis in Mice by Activation of Nrf2 /HO-1/NQO1 Pathway
Qin, Y., Wang, Z., Song, S., Qin, X., Wang, N., Zhou, M., Xu, J., & Zhou, F. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01976-z
“Patients commonly can survive for 3–5 years after diagnosis [1, 2].”
Mou, K., Liang, J., Lv, T., Xin, T., Ye, C., Ma, X., Wang, Z., & Yang, Y. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-04094-x · Cited by 1
“Firstly, diagnosis of PF primarily relies on high-resolution computed tomography (HRCT) or surgical lung biopsy [7], neither is suitable for dynamic monitoring nor assessment of patients with PF.”
Chirag, B. M., Priyanka, P. V., & Subhashini (2026) · Human Gene · doi:10.1016/j.humgen.2026.201533 · Cited by 1
Segmentation and calculation of lung fibrosis in IPF mice by 2.5D UNet
Zheng, Y., Weng, T., Chang, Y., Ma, S., Zhang, J., & Guo, L. (2026) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ae38e5
Yorozuya, T., Saito, A., Sato, T., Takahashi, T., Kameda, M., Yamaguchi, M., SAKUMA, Y., Ichise, N., Tohse, N., Furuhashi, M., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1719710
“Although antifibrotic therapies can slow functional deterioration, the median survival for idiopathic pulmonary fibrosis (IPF), the prototypic ILD, remains poor at only 3–5 years (2, 3), highlighting the need for mechanistic biomarkers and novel therapeutic strategies.”
Zhang, J., Xm, J., Sun, Y., Xia, R., & Chen, F. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.117736
Vastag, Z., Tudorache, E., Trăilă, D., Ciortea, I., Firă-Mladinescu, O., Oancea, C. I., Bogdan, I. G., Suppini, N., & Roşca, E. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031086
“Among these, idiopathic pulmonary fibrosis (IPF) represents the prototypical fibrosing ILD and is associated with substantial morbidity, mortality, and healthcare burden despite advances in diagnostic algorithms and antifibrotic therapy [1–3].”
Spatial omics in pulmonary fibrosis: advancing mechanistic insights and therapeutic strategies
Peng, Y., Yunyun, X. I. E., Yang, F., Xin, Q. I. A. O., & Tian, Y. (2026) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2025-0785
Yin, Y., Wu, X., Liu, Z., Luo, Y., Jing, M., Jing, K., Li, Q., Wang, F., & Huang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761899 · Cited by 1
“Its prevalence and incidence increase with age, mainly affecting middle-aged and older adults (Mortimer et al., 2020), with a higher occurrence in males (Podolanczuk et al., 2023).”
Vernhet, L., Menard, C., Rousseau, C., & Jouneau, S. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101257
Zhao, Y., Leng, M., Wei, B., Xia, H., Ling, M., Bai, X., & Luo, H. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121479
Xu, C., Zhou, Z., Lin, Y., Zhang, S., Cai, S., (43671), B. L., & Wang, Z. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07876-x · Cited by 2
“Although current anti-fibrotic therapies can slow functional decline, IPF remains incurable, reflecting an incomplete understanding of the multicellular programs governing injury, aberrant repair, and scar maturation [3, 4].”
He, W., Ch, F., Liu, M., Qin, H., Wu, Y., Deng, C., & Zhu, X. (2026) · Respiratory Research · doi:10.1186/s12931-026-03612-7
“Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal form of interstitial lung disease of unknown etiology, characterized by relentless fibrotic remodeling of the lung parenchyma, aberrant extracellular matrix (ECM) deposition, and irreversible architectural distortion [1].”
Lipid nanocomposites for precisely triggered Ttc3 gene silencing in pulmonary fibrosis treatment
Li, L., Liang, Y., Yin, P., Lai, Y., JiWei, M. A. I., Wang, Y., He, J., Su, Z., Bai, J., Li, W., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114780
Yang, L., Xie, Y., Yao, Y., Yin, H., Shang, B., Yang, S., You, X., & Ma, J. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-03933-9
“It is characterized by chronic inflammation, progressive lung scarring, disrupted gas exchange, and ultimately respiratory failure and death [1–3].”
Zhou, Y., Zhu, Y., Zhou, Y., Tong, Z., Zhu, X., Du, X., & Dong, Z. (2026) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-026-05644-7
Su, K., Feng, Z., Wang, L., Zhao, G., Wang, J., & Li, J. (2026) · Health and Quality of Life Outcomes · doi:10.1186/s12955-026-02526-8 · Cited by 1
“Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with obscure etiology featuring progressive pulmonary fibrosis [1, 2].”
Cottin, V., Crestani, B., Planès, C., Chambellan, A., Charloux, A., Degano, B., Gille, T., Glérant, J., Jouneau, S., Mewton, N., et al. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101266
Cai, L., Hao, Y., Shio, N. P., Tang, S., Wang, X., Li, Z., & Zhu, J. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11755-5 · Cited by 2
Qi, Q., Wen, S., Niu, L., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102174
Advances in understanding mitophagy's role in lung injury
Du, W., Yang, Y., Zhang, T., Jiang, J., Du, D., Huang, G., & Tao, S. (2026) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2025.06.004 · Cited by 1
“33 Research indicates that during the regeneration of alveolar epithelial cells following bacterial pneumonia, downregulation of mtDNA (MICU1) in AT2 cells leads to reduced differentiation of AT2 into AT1.”
Metadata
- Authors
- Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G.
- Affiliations
- Weill Cornell Medicine (US)
- Mount Auburn Hospital (US)
- Università Cattolica del Sacro Cuore (IT)
- St. Joseph’s Healthcare Hamilton (CA)
- University of Washington (US)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2023-01-26
- Volume
- 61
- Issue
- 4
- Pages
- 2200957
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W4318071623
- Cited by
- 359
- References
- 196
- Citations by year
- 2026: 112 · 2025: 126 · 2024: 101 · 2023: 20
- FWCI
- 65.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, antifibrotic therapy, lung function decline, disease progression, natural history (disease), pathobiology, genetic risk factors, comorbidities, patient monitoring, palliative care, lung transplantation, early detection, diagnosis
- MeSH terms
- Aged, Humans, Tomography, X-Ray Computed, Lung Transplantation, Disease Progression, Early Diagnosis, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.